1 Study Coverage
1.1 Hepatic Encephalopathy Drug Product Introduction
1.2 Market Segments
1.3 Key Hepatic Encephalopathy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type
1.4.2 RBX-2660
1.4.3 KLS-13019
1.4.4 GR-3027
1.4.5 SYNB-1020
1.4.6 Others
1.5 Market by Application
1.5.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hepatic Encephalopathy Drug Market Size, Estimates and Forecasts
2.1.1 Global Hepatic Encephalopathy Drug Revenue 2015-2026
2.1.2 Global Hepatic Encephalopathy Drug Sales 2015-2026
2.2 Global Hepatic Encephalopathy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hepatic Encephalopathy Drug Competitor Landscape by Players
3.1 Hepatic Encephalopathy Drug Sales by Manufacturers
3.1.1 Hepatic Encephalopathy Drug Sales by Manufacturers (2015-2020)
3.1.2 Hepatic Encephalopathy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hepatic Encephalopathy Drug Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hepatic Encephalopathy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drug Revenue in 2019
3.2.5 Global Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hepatic Encephalopathy Drug Price by Manufacturers
3.4 Hepatic Encephalopathy Drug Manufacturing Base Distribution, Product Types
3.4.1 Hepatic Encephalopathy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatic Encephalopathy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hepatic Encephalopathy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatic Encephalopathy Drug Market Size by Type (2015-2020)
4.1.1 Global Hepatic Encephalopathy Drug Sales by Type (2015-2020)
4.1.2 Global Hepatic Encephalopathy Drug Revenue by Type (2015-2020)
4.1.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hepatic Encephalopathy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hepatic Encephalopathy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hepatic Encephalopathy Drug Market Size by Application (2015-2020)
5.1.1 Global Hepatic Encephalopathy Drug Sales by Application (2015-2020)
5.1.2 Global Hepatic Encephalopathy Drug Revenue by Application (2015-2020)
5.1.3 Hepatic Encephalopathy Drug Price by Application (2015-2020)
5.2 Hepatic Encephalopathy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatic Encephalopathy Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hepatic Encephalopathy Drug by Country
6.1.1 North America Hepatic Encephalopathy Drug Sales by Country
6.1.2 North America Hepatic Encephalopathy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hepatic Encephalopathy Drug Market Facts & Figures by Type
6.3 North America Hepatic Encephalopathy Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Hepatic Encephalopathy Drug by Country
7.1.1 Europe Hepatic Encephalopathy Drug Sales by Country
7.1.2 Europe Hepatic Encephalopathy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Type
7.3 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hepatic Encephalopathy Drug by Region
8.1.1 Asia Pacific Hepatic Encephalopathy Drug Sales by Region
8.1.2 Asia Pacific Hepatic Encephalopathy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Type
8.3 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hepatic Encephalopathy Drug by Country
9.1.1 Latin America Hepatic Encephalopathy Drug Sales by Country
9.1.2 Latin America Hepatic Encephalopathy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Type
9.3 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hepatic Encephalopathy Drug by Country
10.1.1 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country
10.1.2 Middle East and Africa Hepatic Encephalopathy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments
11.2 Cosmo Pharmaceuticals S.p.A
11.2.1 Cosmo Pharmaceuticals S.p.A Corporation Information
11.2.2 Cosmo Pharmaceuticals S.p.A Description and Business Overview
11.2.3 Cosmo Pharmaceuticals S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Products Offered
11.2.5 Cosmo Pharmaceuticals S.p.A Related Developments
11.3 Horizon Pharma Plc
11.3.1 Horizon Pharma Plc Corporation Information
11.3.2 Horizon Pharma Plc Description and Business Overview
11.3.3 Horizon Pharma Plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Products Offered
11.3.5 Horizon Pharma Plc Related Developments
11.4 KannaLife Sciences, Inc.
11.4.1 KannaLife Sciences, Inc. Corporation Information
11.4.2 KannaLife Sciences, Inc. Description and Business Overview
11.4.3 KannaLife Sciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Products Offered
11.4.5 KannaLife Sciences, Inc. Related Developments
11.5 Ocera Therapeutics, Inc.
11.5.1 Ocera Therapeutics, Inc. Corporation Information
11.5.2 Ocera Therapeutics, Inc. Description and Business Overview
11.5.3 Ocera Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Products Offered
11.5.5 Ocera Therapeutics, Inc. Related Developments
11.6 Rebiotix Inc.
11.6.1 Rebiotix Inc. Corporation Information
11.6.2 Rebiotix Inc. Description and Business Overview
11.6.3 Rebiotix Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Rebiotix Inc. Hepatic Encephalopathy Drug Products Offered
11.6.5 Rebiotix Inc. Related Developments
11.7 Spherium Biomed S.L.
11.7.1 Spherium Biomed S.L. Corporation Information
11.7.2 Spherium Biomed S.L. Description and Business Overview
11.7.3 Spherium Biomed S.L. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Products Offered
11.7.5 Spherium Biomed S.L. Related Developments
11.8 Umecrine Cognition AB
11.8.1 Umecrine Cognition AB Corporation Information
11.8.2 Umecrine Cognition AB Description and Business Overview
11.8.3 Umecrine Cognition AB Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Products Offered
11.8.5 Umecrine Cognition AB Related Developments
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hepatic Encephalopathy Drug Market Estimates and Projections by Region
12.1.1 Global Hepatic Encephalopathy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.2.2 North America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hepatic Encephalopathy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hepatic Encephalopathy Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatic Encephalopathy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
【掲載企業】
Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB
【免責事項】
https://www.globalresearch.jp/disclaimer